Clinical trials: Eye
Myopia, Hyperopia
Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 1
The purpose of this study was to evaluate the performance of Opti-Free® PureMoist® Multi-Purpose Disinfecting Solution (MPDS) compared to Biotrue™ Multipurpose Solution (MPS) in silicone hydrogel contact lens wearers.
- Conditions
- Myopia, Hyperopia, Contact Lens Comfort
- Trial name
- NCT01684033
- Testing
- Opti-Free® PureMoist® MPDS, Biotrue™ MPS, Habitual contact lenses
- Volunteers
- 207 people
- Sponsor
- Alcon Research
Age-related Macular Degeneration
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth…
- Trial name
- TALON (NCT04005352)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 734 people
- Sponsor
- Novartis Pharmaceuticals
Bacterial Conjunctivitis
A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
This is a 7 day study to evaluate the safety and efficacy of topical gatifloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in subjects from birth to 31 days of age
- Trial name
- NCT00464438
- Testing
- gatifloxacin, moxifloxacin 0.5% eye drops
- Where
- 2 sites in United States, Canada
- Volunteers
- 171 people
- Sponsor
- Allergan
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Chalazion, Hordeolum
Pediatric Zylet Safety and Efficacy Study
A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in children aged 0-6 for the management of lid inflammation (chalazion/hordeolum)
- Trial name
- NCT00420628
- Testing
- loteprednol etabonate/tobramycin opthalmic suspension, vehicle
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Bausch & Lomb Incorporated
Primary Open Angle Glaucoma
The Effects of Caffeinated Coffee on Intraocular Pressure
High intraocular pressure (IOP) is a known risk factor for developing primary open-angle glaucoma (POAG). There is controversy in the literature regarding the degree to which caffeine influences IOP, with some studies reporting…
- Trial name
- NCT01364207
- Testing
- Caffeinated Coffee, Decaffeinated Coffee
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Cataract
Pilot Study of AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL)
The purpose of this study is to describe visual outcomes, in particular spherical equivalent by manifest refraction and visual acuity across a range of distances, 6 months post implantation of the AcrySof® IQ ReSTOR® +3.0 D…
- Trial name
- NCT01200511
- Testing
- AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL
- Volunteers
- 49 people
- Sponsor
- Alcon Research
Stargardt's Disease
Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration
Primary Objective: To assess the safety and tolerability of ascending doses of SAR422459 in participants with Stargardt's Macular Degeneration (SMD). Secondary Objective: To evaluate for possible biological activity of SAR422459.
- Trial name
- NCT01367444
- Testing
- SAR422459
- Where
- 5 sites in United States, France
- Volunteers
- 27 people
- Sponsor
- Sanofi
Diabetic Retinopathy, Posterior Vitreous Detachment
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
The purpose of this study is to assess the efficacy and safety of up to 3 intravitreal injections of ocriplasmin (0.0625mg or 0.125mg), in subjects with moderate to very severe non-proliferative diabetic retinopathy (NPDR), to…
- Conditions
- Diabetic Retinopathy, Posterior Vitreous Detachment, Disease Progression
- Trial name
- CIRCLE (NCT02681809)
- Testing
- ocriplasmin 0.0625mg, ocriplasmin 0.125mg
- Where
- 38 sites in United States, Czechia and 7 more
- Volunteers
- 48 people
- Sponsor
- ThromboGenics
Carotid Stenosis, Atherosclerosis
Revacept in Symptomatic Carotid Stenosis
Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone.
- Conditions
- Carotid Stenosis, Atherosclerosis, Stroke, Transient-ischaemic Attack
- Trial name
- RevaceptCS02 (NCT01645306)
- Testing
- Revacept
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 158 people
- Sponsor
- AdvanceCor GmbH
Cataract
Cataract Surgery: Femto LDV Z8 Versus Conventional
The aim of the study is to demonstrate the performance and safety of the Femtosecond laser-assisted anterior capsulotomy and lens fragmentation on human eyes using the FEMTO LDV Z8 compared to conventional technique in cataract…
- Trial name
- COMFORT (NCT02351271)
- Testing
- Femto LDV Z8, Manual capsulorhexis&lens fragmentation
- Volunteers
- 130 people
- Sponsor
- Ziemer Ophthalmic Systems AG
Child Development
Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso
The use of antibiotics has saved millions of human lives, however consumption of antibiotics can select for antibiotic resistant organisms and may lead to changes in commensal microbiome.
- Trial name
- ARMCA (NCT03187834)
- Testing
- Azithromycin, Amoxicillin, Cotrimoxazole
- Where
- 2 sites in United States, Burkina Faso
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Central Retinal Vein Occlusion
A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
The purpose of this study is to determine whether a fluocinolone sustained drug delivery implant is effective in the treatment of central retinal vein occlusion that has caused persistent macular edema and decreased visual acuity.
- Trial name
- NCT00952614
- Testing
- fluocinolone acetonide (Retisert Implant, Bausch and Lomb)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Glenn Jaffe
Glaucoma
24-hr Intraocular Pressure Control With SIMBRINZA ®
The purpose of this study is to evaluate differences between treatments in mean change from baseline in 24-hr intraocular pressure (IOP) at Week 4.
- Trial name
- NCT02770248
- Testing
- Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Vehicle
- Volunteers
- 162 people
- Sponsor
- Alcon Research
Ocular Inflammation
Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery
To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery
- Trial name
- NCT00645671
- Testing
- 0.5% Loteprednol Etabonate Ophthalmic Ointment, Vehicle of Loteprednol Etabonate Ophthalmic Ointment
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Bausch & Lomb Incorporated
Refractive Error
WaveLight® Refractive Myopic Study
The purpose of this study is to evaluate outcomes of subjects undergoing myopic surgery using the WaveLight® Refractive Suite (Excimer EX500 and Femtosecond FS200 lasers).
- Trial name
- NCT01941498
- Testing
- Wavelight® Refractive Suite, LASIK surgery
- Volunteers
- 104 people
- Sponsor
- Alcon Research
Retinal Vein Occlusion, Diabetic Macular Edema
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
The primary objectives of the study are to evaluate the safety and effect of KPI-121 0.25% ophthalmic suspension and KPI-121 1.0% ophthalmic suspension on intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or…
- Trial name
- Molokini (NCT02245516)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Myopia
A Comparison of Daily Disposable Contact Lenses.
This study seeks to evaluate the clinical performance of a new CE marked daily disposable contact lens that contains a wetting agent to a recently improved daily disposable contact lens.
- Trial name
- NCT00727558
- Testing
- nelfilcon A, narafilcon A
- Where
- 19 sites in United Kingdom
- Volunteers
- 248 people
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Uveitis, Macular Edema
Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
The study is designed to evaluate the safety and efficacy of triamcinolone acetonide, CLS-TA, in subjects with macular edema following non-infectious uveitis.
- Conditions
- Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior
- Trial name
- DOGWOOD (NCT02255032)
- Testing
- 4 mg CLS-TA, 0.8 mg CLS-TA
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Clearside Biomedical, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Patient Preference Comparison of AZARGA Versus COSOPT
The purpose of this study was to assess patient preference regarding ocular comfort of AZARGA® compared to COSOPT® after one week instillation of each study medication.
- Trial name
- NCT01340014
- Testing
- Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension, Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution
- Volunteers
- 112 people
- Sponsor
- Alcon Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.